Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Solid Tumors With Neuroendocrine Differentiation”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06531291
What this trial is testing

Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

Who this might be right for
ESCCBiliary Tract CancerGastric Cancer+1 more
RenJi Hospital 80
Early research (Phase 1)Not Yet RecruitingNCT07252661
What this trial is testing

Study of ACC-1898 in Adult Participants With Advanced Solid Tumors

Who this might be right for
Hepatocellular CarcinomaRenal Cell CarcinomaThyroid Carcinoma, Medullary+6 more
AccSalus Biosciences, Inc. 40
Early research (Phase 1)Active Not RecruitingNCT05538130
What this trial is testing

Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

Who this might be right for
MelanomaGliomaThyroid Cancer+10 more
Pfizer 148
Early research (Phase 1)Ended earlyNCT05605522
What this trial is testing

[225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Who this might be right for
Pancreatic Ductal Adenocarcinoma (PDAC)Squamous Cell Carcinoma of Head and NeckColorectal Cancer+4 more
3B Pharmaceuticals GmbH 19
Early research (Phase 1)Active Not RecruitingNCT04514497
What this trial is testing

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

Who this might be right for
Metastatic Lung Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Neuroendocrine Carcinoma+9 more
National Cancer Institute (NCI) 29
Large-scale testing (Phase 3)Study completedNCT00538850
What this trial is testing

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Who this might be right for
Cancer
INSYS Therapeutics Inc 130
Very early researchEnded earlyNCT00499733
What this trial is testing

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

Who this might be right for
Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Not applicableNot Yet RecruitingNCT06156332
What this trial is testing

Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy

Who this might be right for
Advanced Solid Tumors With Neuroendocrine Differentiation
Shanghai Changzheng Hospital 39
Testing effectiveness (Phase 2)Ended earlyNCT05126433
What this trial is testing

Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorUrothelial Cancer+2 more
Jazz Pharmaceuticals 47
Testing effectiveness (Phase 2)Study completedNCT03365791
What this trial is testing

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Who this might be right for
Small Cell Lung CancerGastric AdenocarcinomaEsophageal Adenocarcinoma+5 more
Novartis Pharmaceuticals 76
Early research (Phase 1)Active Not RecruitingNCT04514484
What this trial is testing

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Who this might be right for
Advanced Differentiated Thyroid Gland CarcinomaAdvanced Head and Neck CarcinomaAdvanced Hepatocellular Carcinoma+60 more
National Cancer Institute (NCI) 8